Back to Peptides

TB-500

Healing & Regeneration

TB-500 is a synthetic peptide modeled after Thymosin Beta-4 that promotes tissue regeneration, reduces inflammation, and supports recovery in musculoskeletal injuries. It is often used by researchers and clinicians for its potent actin-binding properties and ability to enhance healing in muscles, tendons, ligaments, and even cardiac tissue.

Reconstitute
3 mL BAC + 10mg vial
33 mcg/unit
Daily Range
2–3 mg Subcutaneous (SQ)
every other day (loading); weekly (maintenance)
Standard Dose
2.5 mg
Cycle
4–8 weeks
then reassess
HealingInflammation reductionTissue repair

Dosing & Reconstitution Guide

In preclinical studies, TB-500 has been administered at 2.0 mg per week (typically divided into two doses), depending on the animal model and tissue target. These regimens are investigational and not authorized for human application..

Standard / Gradual Approach

5mg Vialstandard
PhaseDoseVolume
Weeks 1–41,250 mcg (1.25 mg)50 units (0.50 mL)
Weeks 5–121,250 mcg (1.25 mg)50 units (0.50 mL)

Standard / Gradual Approach

5mg Vialadvanced
PhaseDoseVolume
Weeks 1–2250 mcg (0.25 mg)10 units (0.10 mL)
Weeks 3–8500 mcg (0.50 mg)20 units (0.20 mL)
Weeks 9–12250 mcg (0.25 mg)10 units (0.10 mL)

Protocol Summary

Subcutaneous (SQ): every other day (loading); weekly (maintenance) · Dose range 2–3 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Loading Phase: 2.5 mg subQ injection every other day for 4–6 weeks. Maintenance Phase: 2 mg subQ injection once weekly.

🧪 Quick Start

Vial Size
10 mg
BAC Water
3 mL
Concentration
3.33 mcg/unit

Potential Benefits & Use Cases

TB-500 is a research-use-only peptide. It is not approved for human or veterinary use. The content provided here is based on preclinical studies and is for educational reference only.
Supports accelerated wound healing through enhanced angiogenesis and cell migration (preclinical)
Stimulates keratinocyte migration 2–3 fold, achieving 42% reepithelialization at 4 days (preclinical)
Demonstrates anti-fibrotic effects — prevents fibroblast-to-myofibroblast conversion, reduces scarring (preclinical)
Enhances collagen deposition and improves tendon strength and elasticity (preclinical)
Reduces inflammation via thymosin pathways in multiple tissue types (preclinical)
Clinical data Strong preclinical Limited data

Mechanism of Action

→Promotes cell migration
→Enhances collagen deposition
→Reduces inflammation
→Upregulates actin-binding proteins to enhance cytoskeletal repair
→Improves angiogenesis and tissue oxygenation
→Supports endothelial integrity and cardiac repair

Lifestyle & Optimization

timing

2x weekly during loading, then weekly maintenance.

diet

Adequate protein for tissue repair.

exercise

Balance activity and rest during injury recovery.

sleep

Sleep 7–9 hours. Stress management.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
International Journal of Molecular Medicine — Thymosin β4 activates integrin-linked kinase for wound healingReference
Annals of the New York Academy of Sciences — Thymosin β4: actin-sequestering protein regulates cell motilityReference
FASEB Journal — Thymosin β4 promotes survival of cardiomyocytesReference
Expert Opinion on Biological Therapy — Clinical applications of thymosin β4Reference
RegeneRx — Thymosin Beta 4 clinical development pipelineReference
ClinicalTrials.gov — NCT02016378: RGN-259 Phase 3 for dry eyeReference

Side Effects & Safety

Common Side Effects

• Headaches, especially first few days
• Slight energy drop early in treatment

Contraindications & Warnings

• Possible BP decreases, dizziness, palpitations at higher doses
• Anaphylaxis risk in hypersensitive individuals

🧮 Dose Calculator

Concentration
33.3
mcg/unit
Draw Volume
15
units (0.150 mL)
For a 500 mcg dose, draw 15 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
Generally high and effective for systemic action.
Oral Administration
Poor due to enzymatic degradation in the digestive system.
Intranasal
Intramuscular delivery is equally or more effective than SubQ for local injuries.
Half-Life
1–2 days
Degradation
Metabolized primarily in the liver.
Tissue Specificity
Affects muscle, connective tissues, and tendons.
⚗️

Peptide Details

Molecular Weight
4963.49
Formula
C212H350N56O78S
Sequence
Ac-Ser-Asp-Lys-Pro-Thr-Phe-Ser-Pro-Lys-Glu-Lys-Lys-Cys-Asp-Glu-Leu-Ser-Kys-Leu-Tyr-Glu-Asp-Gly-Asp-Tyr-Phe-Ser-Asp-Cys-Phe-Leu-Cys-His-Val
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution as freezing can denature peptides